Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

About this update from Novavax, Inc.

[{"type":"text","content":"GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.\nConference Details:\nPresentation and Q&A\nDate:\nMonday, January 8, 2024\nTime:\n5:15 – 5:55 p.m. Pacific Standard Time (PST)\nLocation:\nWestin St. Francis Hotel in San Francisco, California\nModerator:\nEric Joseph, Ph.D., Executive Director, Biotechnology Equity Research\nNovavax participants:\nJohn C. Jacobs, President and Chief Executive Officer\nConference\nEvent:\nInvestor Meetings\nDate:\nMonday, January 8, 2024\nRecordingsA replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.\nAbout NovavaxNovavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.\nContacts:InvestorsErika [email protected] \nMediaAli [email protected]\n\n \n\n\n\n\n View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-the-42nd-annual-jp-morgan-healthcare-conference-302024821.html\nSOURCE NOVAVAX, INC","length":14709,"tagName":"div"}]

More updates from Novavax, Inc.